宋婷婷,陈韬,荆晶,王清松,卢旭,汪奇,陈韵岱,郭军

• 1:解放军医学院
• 2:解放军总医院第一医学中心心血管内科

摘要(Abstract)：

目的评价药物涂层球囊(DCB)在经皮冠状动脉介入治疗(PCI)中的使用趋势。方法收集2015年3月至2020年2月因冠状动脉粥样硬化性心脏病在解放军总医院第一医学中心行PCI的患者数据,统计近5年来DCB的使用情况,将DCB在支架内再狭窄与原发血管病变中的使用进行比较,并针对原发病变中的应用进一步分析。结果 2015年3月至2020年2月共18 377例患者接受PCI,其中934例使用DCB,其在PCI患者中的使用占比由1.71%增加至10.31%(P<0.001)。在使用DCB的患者中,支架内再狭窄563例(60.28%);原发病变371例(39.72%),原发血管病变DCB使用由2015年的28例增长为2019年的167例,2015年DCB在原发病变治疗中的使用占比0.98%(28/2849),与2019年4.72%(167/3538)比较,差异有统计学意义(P<0.001),提示DCB在原发病变治疗中各年份间存在线性关系,皮尔森R=–0.09。应用DCB处理原发小血管病变(参考血管直径<2.75 mm)由2015年4.71%(21/446)增至2019年17.49%(124/709),原发大血管病变(参考血管直径≥2.75 mm)的DCB使用0.29%(7/2403)增至1.52%(43/2829)。DCB在原发小血管中应用稳步增长,在原发大血管病变中的使用也逐渐增多,但差异无统计学意义(P=0.720)。左前降支从2015年0.56%(7/1241)增至2019年3.95%(62/1569),差异有统计学意义(P<0.001);左回旋支从1.31%(6/457)增至6.20%(37/597),差异有统计学意义(P<0.001);右冠状动脉从0.22%(2/921)增至2.52%(26/1030),差异有统计学意义(P<0.001);边支血管从5.65%(13/230)增至12.28%(42/342),差异有统计学意义(P=0.006)。DCB在不同部位原发病变中的应用存在线性关系,皮尔森R=–0.17。结论 DCB在PCI中的应用逐年增加,不仅作为处理支架内再狭窄病变的重要策略得到越来越多的临床应用,同时在冠状动脉原发病变中的应用也明显增加,并且在原发大血管病变和原发小血管病变中的应用呈同步增加趋势,尤其是在左前降支病变中也得到了越来越多的应用。

关键词(KeyWords)： 经皮冠状动脉介入治疗;药物涂层球囊;原发血管病变

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划项目（2018YFC2001200）;; 北京市科技新星项目（Z18100006218120）;; 全军青年人才托举计划（17-JCJQ-QT-029）

作者(Author): 宋婷婷,陈韬,荆晶,王清松,卢旭,汪奇,陈韵岱,郭军

参考文献(References)：

• [1]中华医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南（2016）.中华心血管病杂志，2016, 44(5):382-400.
• [2] Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans:delayed healing and late thrombotic risk. J Am Coll Cardiol, 2006. 48(1):193-202.
• [3] Godino C, Furuichi S, Latib A, et al. Clinical and angiographic followup of small vessel lesions treated with paclitaxel-eluting stents(from the TRUE Registry). Am J Cardiol, 2008, 102(8):1002-1008.
• [4] Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Kardiol Pol, 2014, 72(12):1253-379.
• [5]陈韵岱，王建安，刘斌，等.药物涂层球囊临床应用中国专家共识.中国介入心脏病学杂志，2016, 24(2):61-67.
• [6] Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease:third report of the international dcb consensus group. JACC Cardiovasc Interv, 2020, 13(12):1391-1402.
• [7] Venetsanos D, Lawesson SS, Panayi G, et al. Long-term e fficacy of drug coated balloons compared with new generation drug-eluting stents for the treatment of de novo coronary artery lesions. Catheter Cardiovasc Interv, 2018, 92(5):E317-E326.
• [8] Liu Y, Zhang YJ, Deng LX, et al. 12-Month clinical results of drug-coated balloons for de novo coronary lesion in vessels exceeding3.0 mm. Int J Cardiovasc Imaging, 2019, 35(4):579-586.
• [9] Kleber FX, Rittger H, Bonaventura K, et al. Drug-coated balloons for treatment of coronary artery disease:updated recommendations from a consensus group. Clin Res Cardiol, 2013, 102(11):785-797.
• [10] Hong MK, Lee SY. Diff erential eff ects of drug-coated balloon angioplasty for in-stent restenosis. J Am Coll Cardiol, 2020, 75(21):2679-2681.
• [11] Xu B, Qian J, Ge J, et al. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial:a prospective, multicenter,randomized trial for the treatment of drug-eluting stent in-stent restenosis.Catheter Cardiovasc Interv, 2016, 87 Suppl 1:624-629.
• [12] Xi Y, Chen J, Bi Y, et al. Long-term clinical safety and e fficacy of drug-coated balloon in the treatment of in-stent restenosis:a metaanalysis and systematic review. Catheter Cardiovasc Interv, 2020,96(2):E129-E141.
• [13] Hee L, Terluk A, Thomas L, et al. Late clinical outcomes for Se Quent please paclitaxel-coated balloons in PCI of instent restenosis and de novo lesions:a single-center, real world registry. Catheter Cardiovasc Interv, 2017, 89(3):375-382.
• [14] Her AY, Ann SH, Singh GB, et al. Serial morphological changes of side-branch ostium after paclitaxel-coated balloon treatment of de novo coronary lesions of main vessels. Yonsei Med J, 2016,57(3):606-613.
• [15] Cortese B, Piraino D, Buccheri D, et al. Treatment of bifurcation lesions with drug-coated balloons:a review of currently available scientific data. Int J Cardiol, 2016,220:589-594.
• [16] Mitomo S, Jabbour RJ, Mangieri A, et al. Mid-term clinical outcomes after bailout drug-eluting stenting for suboptimal drugcoated balloon results:insights from a Milan registry. Int J Cardiol,2018,263:17-23.
• [17] Scheller B, Speck U, Abramjuk C, Bernhardt U, B?hm M, Nickenig G.Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation, 2004, 110(7):810-814.
• [18] Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart,2010,96(16):1291-1296.
• [19] Sanz Sánchez J, Chiarito M, Cortese B, et al. Drug-Coated balloons vs drug-eluting stents for the treatment of small coronary artery disease:a meta-analysis of randomized trials. Catheter Cardiovasc Interv, 2020,98(1):66-65.
• [20] Her AY, Shin ES, Lee JM, et al. Paclitaxel-coated balloon treatment for functionally nonsignificant residual coronary lesions after balloon angioplasty. Int J Cardiovasc Imaging, 2018, 34(9):1339-1347.
• [21] Yu X, Ji F, Xu F, et al. Treatment of large de novo coronary lesions with paclitaxel-coated balloon only:results from a Chinese institute.Clin Res Cardiol, 2019,108(3):234-243.
• [22]方素霞，蒋峻.药物涂层球囊处理冠状动脉左前降支开口原位病变的临床疗效.心电与循环，2020, 39(3):232-235.